Identification

Generic Name
Talactoferrin alfa
DrugBank Accession Number
DB05426
Background

Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.

Type
Biotech
Groups
Investigational
Synonyms
  • Talactoferrin alfa
  • Talactoferrin alpha
External IDs
  • LF-00
  • LF00

Pharmacology

Indication

Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Oral talactoferrin stimulated the production of the immunostimulatory cytokine IL-18 in mice, increasing IL-18 levels both in the gut and in systemic circulation. Oral talactoferrin was also shown to stimulate the activity of NK cells and to increase the production and activity of key circulating immune cells.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
ArticaineThe risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Bupivacaine.
ButacaineThe risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Butacaine.
ButambenThe risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Butamben.
CapsaicinThe risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Capsaicin.
ChloroprocaineThe risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Chloroprocaine.
CinchocaineThe risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Cinchocaine.
CocaineThe risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Cocaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
7A055A9QRR
CAS number
308240-58-6

References

General References
  1. Lyons TE, Miller MS, Serena T, Sheehan P, Lavery L, Kirsner RS, Armstrong DG, Reese A, Yankee EW, Veves A: Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg. 2007 Jan;193(1):49-54. [Article]
PubChem Compound
192716
PubChem Substance
175427001
ChemSpider
167235
RxNav
1425932
ZINC
ZINC000150376965

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentNon-Small Cell Lung Cancer (NSCLC)1
3Unknown StatusTreatmentNon-Small Cell Lung Cancer (NSCLC)1
2CompletedTreatmentSevere Sepsis1
2, 3SuspendedTreatmentSevere Sepsis1
1, 2Unknown StatusPreventionHospital Acquired Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created at November 18, 2007 18:24 / Updated at February 21, 2021 18:51